Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure isn Type 1 diabetes.
Affiliation
Department of Medicine, Cork University Hospital, Wilton, Cork, Ireland., b.ferriss@ucc.ieIssue Date
2012-02-03T15:05:20ZMeSH
AdolescentAdult
Blood Glucose/*analysis
Blood Pressure/physiology
Cholesterol/blood
Diabetes Mellitus, Type 1/metabolism/*physiopathology
Drug Administration Schedule
Female
Hemoglobin A, Glycosylated/analysis
Humans
Hypoglycemic Agents/administration & dosage
Injections
Insulin/administration & dosage
Lipids/*blood
Lipoproteins/blood
Male
Middle Aged
Prospective Studies
Triglycerides/blood
Waist-Hip Ratio
Weight Gain/*physiology
Metadata
Show full item recordCitation
Diabet Med. 2006 May;23(5):557-64.Journal
Diabetic medicine : a journal of the British Diabetic AssociationDOI
10.1111/j.1464-5491.2006.01847.xPubMed ID
16681565Abstract
AIMS: To assess the effects of weight gain on metabolic control, plasma lipids and blood pressure in patients with Type 1 diabetes. METHODS: Patients in the EURODIAB Prospective Complications Study (n = 3250) were examined at baseline and 1800 (55%) were re-examined a mean of 7.3 years later. Patients had Type 1 diabetes, defined as a diagnosis made before age 36 years and with a need for continuous insulin therapy within a year of diagnosis. Patients were aged 15-60 years at baseline and were stratified for age, sex and duration of diabetes. RESULTS: The change in HbA(1c) from baseline to follow-up examination was significantly more favourable in those who gained 5 kg or more during follow-up ('marked weight gain') than in patients who gained less or no weight or lost weight ('less or no weight gain'). In those with marked weight gain, there was a significantly greater rise in plasma triglycerides and total cholesterol and significantly less favourable changes in low-density lipoprotein and high-density lipoprotein cholesterol compared with those with less or no weight gain, with or without adjustment for HbA(1c). Systolic and diastolic blood pressure also rose significantly more in the group with marked weight gain. CONCLUSION: Weight gain in patients with Type 1 diabetes has adverse effects on plasma lipids and blood pressure, despite a small improvement in glycaemic control.Language
engISSN
0742-3071 (Print)0742-3071 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1111/j.1464-5491.2006.01847.x
Scopus Count
Collections
Related articles
- Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
- Authors: Davis TM, Cull CA, Holman RR, U.K. Prospective Diabetes Study (UKPDS) Group
- Issue date: 2001 Jul
- Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study.
- Authors: Citro G, Lorusso B, Rossi A, Romaniello M, Gentilella R, Cremasco F
- Issue date: 2009 Sep
- Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.
- Authors: Becker A, van der Does FE, van Hinsbergh VW, Heine RJ, Bouter LM, Stehouwer CD
- Issue date: 2003 Apr
- Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.
- Authors: Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD
- Issue date: 1998 Jul 8
- Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
- Authors: Berhanu P, Perez A, Yu S
- Issue date: 2007 Jul